Genetics of nonpharmacological treatments of depression.
Journal
Psychiatric genetics
ISSN: 1473-5873
Titre abrégé: Psychiatr Genet
Pays: England
ID NLM: 9106748
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
entrez:
9
1
2023
pubmed:
10
1
2023
medline:
11
1
2023
Statut:
ppublish
Résumé
Nonpharmacological antidepressant treatments are effective and well tolerated in selected patients. However, response is heterogeneous and validated biomarkers would be precious to aid treatment choice. We searched Pubmed, Scopus, and Google Scholar until May 2022 for original articles evaluating the association of genetic variables with the efficacy of nonpharmacological treatments for major depressive episodes. Most studies analyzed small sample sizes using the candidate gene approach, leading to poorly replicated findings that need to be interpreted cautiously. The few available methylome-wide and genome-wide association studies (GWASs) considered only electroconvulsive therapy (ECT) and cognitive-behavioral therapy in small samples, providing interesting findings by using polygenic risk scores. A deeper knowledge of the genetic factors implicated in treatment response may lead to a better understanding of the neurobiological mechanisms of nonpharmacological therapies for depression, and depression itself. Future GWAS are going to expand their sample size, thanks to consortia such as the gen-ECT-ic consortium.
Identifiants
pubmed: 36617741
doi: 10.1097/YPG.0000000000000332
pii: 00041444-202302000-00001
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-7Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361:799–808.
WHO. (2019). The global burden of disease: 2019 update. World Health Organization.
Andersson E, Crowley JJ, Lindefors N, Ljótsson B, Hedman-Lagerlöf E, Boberg J, et al. (2019). Genetics of response to cognitive behavior therapy in adults with major depression: a preliminary report. Mol Psychiatry 24:484–490.
Anttila S, Huuhka K, Huuhka M, Rontu R, Mattila KM, Leinonen E, et al. (2007). Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression. J Neural Transm (Vienna) 114:461–468.
Anttila S, Huuhka K, Huuhka M, Illi A, Rontu R, Leinonen E, et al. (2008). Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharmacogenomics J 8:113–116.
Anttila S, Viikki M, Huuhka K, Huuhka M, Huhtala H, Rontu R, et al. (2009). TPH2 polymorphisms may modify clinical picture in treatment-resistant depression. Neurosci Lett 464:43–46.
Austelle CW, O’Leary GH, Thompson S, Gruber E, Kahn A, Manett AJ, et al. (2021). A comprehensive review of vagus nerve stimulation for depression. Neuromodulation 6:1.
Baghai TC, Schule C, Zwanzger P, Zill P, Ella R, Eser D, et al. (2003). Influence of a functional polymorphism within the angiotensin I-converting enzyme gene on partial sleep deprivation in patients with major depression. Neurosci Lett 339:223–226.
Barbini B, Attanasio F, Manfredi E, Cavallini MC, Zanardi R, Colombo C (2021). Bright light therapy accelerates the antidepressant effect of repetitive transcranial magnetic stimulation in treatment resistant depression: a pilot study. Int J Psychiatry Clin Pract 25:375–377.
Benedetti F (2012). Antidepressant chronotherapeutics for bipolar depression. Dialogues Clin Neurosci 14:401–411.
Benedetti F, Colombo C, Serretti A, Lorenzi C, Pontiggia A, Barbini B, et al. (2003). Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Biol Psychiatry 54:687–692.
Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E (2004). A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 368:123–126.
Benedetti F, Barbini B, Bernasconi A, Fulgosi MC, Colombo C, Dallaspezia S, et al. (2008). Serotonin 5-HT2A receptor gene variants influence antidepressant response to repeated total sleep deprivation in bipolar depression. Prog Neuropsychopharmacol Biol Psychiatry 32:1863–1866.
Benedetti F, Barbini B, Bernasconi A, Fulgosi MC, Dallaspezia S, Gavinelli C, et al. (2010). Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val(108/158)Met polymorphism. J Affect Disord 121:68–72.
Bennett DM, Currie J, Fernie G, Perrin JS, Reid IC (2016). Differences in cognitive outcomes after ECT depending on BDNF and COMT polymorphisms. J ECT 32:243–250.
Bocchio-Chiavetto L, Miniussi C, Zanardini R, Gazzoli A, Bignotti S, Specchia C, et al. (2008). 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett 437:130–134.
Border R, Johnson EC, Evans LM, Smolen A, Berley N, Sullivan PF, et al. (2019). No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. Am J Psychiatry 176:376–387.
Bousman CA, Katalinic N, Martin DM, Smith DJ, Ingram A, Dowling N, et al. (2015). Effects of COMT, DRD2, BDNF, and APOE genotypic variation on treatment efficacy and cognitive side effects of electroconvulsive therapy. J ECT 31:129–135.
Bruijniks SJE, van Grootheest G, Cuijpers P, de Kluiver H, Vinkers CH, Peeters F, et al. (2020). Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression. J Psychiatr Res 130:424–432.
Brunoni AR, Kemp AH, Shiozawa P, Cordeiro Q, Valiengo LC, Goulart AC, et al. (2013). Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system. Eur Neuropsychopharmacol 23:1530–1540.
Brunoni AR, Carracedo A, Amigo OM, Pellicer AL, Talib L, Carvalho AF, et al. (2020). Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. Braz J Psychiatry 42:128–135.
Cheng CM, Hong CJ, Lin HC, Chu PJ, Chen MH, Tu PC, et al. (2022). Predictive roles of brain-derived neurotrophic factor Val66Met polymorphism on antidepressant efficacy of different forms of prefrontal brain stimulation monotherapy: a randomized, double-blind, sham-controlled study. J Affect Disord 297:353–359.
Choi SW, Mak TS, O’Reilly PF (2020). Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc 15:2759–2772.
Ciobanu C, Girard M, Marin B, Labrunie A, Malauzat D (2013). rTMS for pharmacoresistant major depression in the clinical setting of a psychiatric hospital: effectiveness and effects of age. J Affect Disord 150:677–681.
Clements CC, Karlsson R, Lu Y, Juréus A, Rück C, Andersson E, et al. (2021). Genome-wide association study of patients with a severe major depressive episode treated with electroconvulsive therapy. Mol Psychiatry 26:2429–2439.
Dall’Aglio L, Lewis CM, Pain O (2021). Delineating the genetic component of gene expression in major depression. Biol Psychiatry 89:627–636.
Dallaspezia S, Locatelli C, Lorenzi C, Pirovano A, Colombo C, Benedetti F (2016). Sleep homeostatic pressure and PER3 VNTR gene polymorphism influence antidepressant response to sleep deprivation in bipolar depression. J Affect Disord 192:64–69.
Dandekar MP, Fenoy AJ, Carvalho AF, Soares JC, Quevedo J (2018). Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications. Mol Psychiatry 23:1094–1112.
Dannlowski U, Domschke K, Birosova E, Lawford B, Young R, Voisey J, et al. (2013). Dopamine D 3 receptor gene variation: impact on electroconvulsive therapy response and ventral striatum responsiveness in depression. Int J Neuropsychopharmacol 16:1443–1459.
Domschke K, Zavorotnyy M, Diemer J, Nitsche S, Hohoff C, Baune BT, et al. (2010). COMT val158met influence on electroconvulsive therapy response in major depression. Am J Med Genet B Neuropsychiatr Genet 153B:286–290.
Fabbri C, Montgomery S, Lewis CM, Serretti A (2020). Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. Int Clin Psychopharmacol 35:233–242.
Faisal-Cury A, Ziebold C, Rodrigues DMO, Matijasevich A (2022). Depression underdiagnosis: prevalence and associated factors. A population-based study. J Psychiatr Res. 151:157–165.
Farah WH, Alsawas M, Mainou M, Alahdab F, Farah MH, Ahmed AT, et al. (2016). Non-pharmacological treatment of depression: a systematic review and evidence map. Evid Based Med 21:214–221.
Fava M (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649–659.
Friedrich MJ (2017). Depression is the leading cause of disability around the world. JAMA 317:1517.
Gur E, Lerer B, Dremencov E, Newman ME (2000). Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. Neuroreport 11:2925–2929.
Haggarty SJ, Karmacharya R, Perlis RH (2021). Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Mol Psychiatry 26:168–185.
Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015). Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry 76:1374–1384.
Hopman HJ, Chan SMS, Chu WCW, Lu H, Tse CY, Chau SWH, et al. (2021). Personalized prediction of transcranial magnetic stimulation clinical response in patients with treatment-refractory depression using neuroimaging biomarkers and machine learning. J Affect Disord 290:261–271.
Humpston C, Benedetti F, Serfaty M, Markham S, Hodsoll J, Young AH, et al. (2020). Chronotherapy for the rapid treatment of depression: a meta-analysis. J Affect Disord 261:9191102–9191102.
Huuhka M, Anttila S, Leinonen E, Huuhka K, Rontu R, Mattila KM, et al. (2005). The apolipoprotein E polymorphism is not associated with response to electroconvulsive therapy in major depressive disorder. J ECT 21:7–11.
Huuhka K, Anttila S, Huuhka M, Leinonen E, Rontu R, Mattila K, et al. (2007). Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 257:31–35.
Huuhka K, Kampman O, Anttila S, Huuhka M, Rontu R, Mattila KM, et al. (2008). RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder. Neurosci Lett 437:25–28.
Kautto M, Kampman O, Mononen N, Lehtimäki T, Haraldsson S, Koivisto PA, et al. (2015). Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression. Neurosci Lett 590:116–120.
Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S (2019). Prognosis and improved outcomes in major depression: a review. Transl Psychiatry 9:127.
Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018). Clin Neurophysiol 131:474–528.
Li JM, Zhang Y, Su WJ, Liu LL, Gong H, Peng W, et al. (2018). Cognitive behavioral therapy for treatment-resistant depression: a systematic review and meta-analysis. Psychiatry Res 268:243–250.
Lin Z, He H, Zhang C, Wang Z, Jiang M, Li Q, et al. (2015). Influence of Val108/158Met COMT gene polymorphism on the efficacy of modified electroconvulsive therapy in patients with treatment resistant depression. Cell Biochem Biophys 71:1387–1393.
Maffioletti E, Gennarelli M, Gainelli G, Bocchio-Chiavetto L, Bortolomasi M, Minelli A (2019). BDNF genotype and baseline serum levels in relation to electroconvulsive therapy effectiveness in treatment-resistant depressed patients. J ECT 35:189–194.
Malaguti A, Rossini D, Lucca A, Magri L, Lorenzi C, Pirovano A, et al. (2011). Role of COMT, 5-HT(1A), and SERT genetic polymorphisms on antidepressant response to transcranial magnetic stimulation. Depress Anxiety 28:568–573.
McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, et al.; National Network of Depression Centers rTMS Task GroupNational Network of Depression Centers rTMS Task Group. (2018). Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry 79:16cs10905.
Minelli A, Congiu C, Ventriglia M, Bortolomasi M, Bonvicini C, Abate M, et al. (2016). Influence of GRIK4 genetic variants on the electroconvulsive therapy response. Neurosci Lett 626:94–98.
Moschny N, Zindler T, Jahn K, Dorda M, Davenport CF, Wiehlmann L, et al. (2020). Novel candidate genes for ECT response prediction-a pilot study analyzing the DNA methylome of depressed patients receiving electroconvulsive therapy. Clin Epigenetics 12:114.
Nakagawa A, Mitsuda D, Sado M, Abe T, Fujisawa D, Kikuchi T, et al. (2017). Effectiveness of supplementary cognitive-behavioral therapy for pharmacotherapy-resistant depression: a randomized controlled trial. J Clin Psychiatry 78:1126–1135.
Neyazi A, Theilmann W, Brandt C, Rantamäki T, Matsui N, Rhein M, et al. (2018). P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy. Transl Psychiatry 8:25.
Peters RB, Xavier J, Mondin TC, Cardoso TA, Ferreira FB, Teixeira L, et al. (2021). BDNF Val66Met polymorphism and resilience in major depressive disorder: the impact of cognitive psychotherapy. Braz J Psychiatry 43:22–28.
Pinna M, Manchia M, Oppo R, Scano F, Pillai G, Loche AP, et al. (2018). Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review. Neurosci Lett 669:32–42.
Rasmussen KG, Black JL (2009). Serotonin transporter gene status and electroconvulsive therapy outcomes: a retrospective analysis of 83 patients. J Clin Psychiatry 70:92–94.
Rayner C, Coleman JRI, Purves KL, Hodsoll J, Goldsmith K, Alpers GW, et al. (2019). A genome-wide association meta-analysis of prognostic outcomes following cognitive behavioural therapy in individuals with anxiety and depressive disorders. Transl Psychiatry 9:150.
Rezaei M, Shariat Bagheri MM, Ahmadi M (2021). Clinical and demographic predictors of response to anodal tDCS treatment in major depression disorder (MDD). J Psychiatr Res 138:68–74.
Rossini D, Magri L, Lucca A, Giordani S, Smeraldi E, Zanardi R (2005). Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial. J Clin Psychiatry 66:1569–1575.
Ryan KM, Dunne R, McLoughlin DM (2018). BDNF plasma levels and genotype in depression and the response to electroconvulsive therapy. Brain Stimul 11:1123–1131.
Sato S, Bunney B, Mendoza-Viveros L, Bunney W, Borrelli E, Sassone-Corsi P, et al. (2022). Rapid-acting antidepressants and the circadian clock. Neuropsychopharmacology 47:805–816.
Schosser A, Fischer-Hansal D, Swoboda MM, Ludwig B, Carlberg L, Swoboda P, et al. (2022). BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression: to be submitted to: European Neuropsychopharmacology. Eur Neuropsychopharmacol 58:103–108.
Schumann G, Benedetti F, Voderholzer U, Kammerer N, Hemmeter U, Travers HW, et al. (2001). Antidepressive response to sleep deprivation in unipolar depression is not associated with dopamine D3 receptor genotype. Neuropsychobiology 43:127–130.
Serretti A, Cusin C, Benedetti F, Mandelli L, Pirovano A, Zanardi R, et al. (2005). Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet 137B:36–39.
Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, et al. (2021). A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry 27:1286–1299.
Sirignano L, Frank J, Kranaster L, Witt SH, Streit F, Zillich L, et al. (2021). Methylome-wide change associated with response to electroconvulsive therapy in depressed patients. Transl Psychiatry 11:347.
Soda T, McLoughlin DM, Clark SR, Oltedal L, Kessler U, Haavik J, et al. (2020). International consortium on the genetics of electroconvulsive therapy and severe depressive disorders (Gen-ECT-ic). Eur Arch Psychiatry Clin Neurosci 270:921–932.
Van Diermen L, van den Ameele S, Kamperman AM, Sabbe BCG, Vermeulen T, Schrijvers D, et al. (2018). Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br J Psychiatry 212:71–80.
Viikki ML, Järventausta K, Leinonen E, Huuhka M, Mononen N, Lehtimäki T, et al. (2013). BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression. Psychiatr Genet 23:134–136.
Voigt JD, Leuchter AF, Carpenter LL (2021). Theta burst stimulation for the acute treatment of major depressive disorder: a systematic review and meta-analysis. Transl Psychiatry 11:330.
Voineskos D, Daskalakis ZJ, Blumberger DM (2020). Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat 16:221–234.
Zanardi R, Magri L, Rossini D, Malaguti A, Giordani S, Lorenzi C, et al. (2007). Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression. Eur Neuropsychopharmacol 17:651–657.
Zanardi R, Poletti S, Prestifilippo D, Attanasio F, Barbini B, Colombo C (2020). Transcranial direct current stimulation: a novel approach in the treatment of vascular depression. Brain Stimul 13:1559–1565.
Zanardi R, Manfredi E, Montrasio C, Colombo C, Serretti A, Fabbri C (2021a). Pharmacogenetic-guided treatment of depression: real-world clinical applications, challenges, and perspectives. Clin Pharmacol Ther 110:573–581.
Zanardi R, Prestifilippo D, Fabbri C, Colombo C, Maron E, Serretti A (2021b). Precision psychiatry in clinical practice. Int J Psychiatry Clin Pract 25:19–27.